VIRX — Viracta Therapeutics Balance Sheet
0.000.00%
- $0.66m
- -$3.57m
Annual balance sheet for Viracta Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 29.1 | 20.4 | 104 | 91 | 53.7 |
Net Total Receivables | — | — | — | — | 0.281 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 36.3 | 22.1 | 105 | 93.7 | 55 |
Net Property, Plant And Equipment | 0.82 | 0.273 | 0.882 | 0.414 | 0.464 |
Other Long Term Assets | |||||
Total Assets | 37.2 | 23.2 | 109 | 96 | 56.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 9.42 | 3.31 | 9.08 | 10 | 38.4 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.7 | 3.31 | 14.2 | 34.9 | 38.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 27.5 | 19.9 | 94.4 | 61.1 | 18.3 |
Total Liabilities & Shareholders' Equity | 37.2 | 23.2 | 109 | 96 | 56.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |